OncoC4 operates as a privately-owned, clinical-phase biopharmaceutical organization focused on the exploration and advancement of innovative biologicals for the treatment of cancer. The company possesses a series of pioneering immunotherapy products undergoing preclinical evaluation. Founded in 2000 based on the scientific breakthroughs of its creators, OncoC4 has progressed its primary product, CD24Fc, from a foundational idea to clinical trials for various indications. In response to the global battle against COVID-19, OncoImmune has successfully concluded a Phase III clinical study, SAC-COVID, demonstrating the significant enhancement of clinical recovery with CD24Fc.